Association of reduced red blood cell deformability and diabetic nephropathy

Kidney International

Volumn 67, Issue 1, 2005, Pages 295-300

  Brown, Clinton D ^a   Ghali, Halim S ^a   Zhao, Zhonghua ^a   Thomas, Lorraine L ^a   Friedman, Eli A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Advanced glycation end products; Diabetes; Nephropathy; Red blood cell deformability

Indexed keywords

CREATININE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CREATININE BLOOD LEVEL; DETERIORATION; DIABETIC NEPHROPATHY; ERYTHROCYTE DEFORMABILITY; FEMALE; HUMAN; KIDNEY FAILURE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 10944255773     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00082.x     Document Type: Article

References (35)

1. MAUER SM, CHAVERS BM: A comparison of kidney disease in tape I and type II diabetes. Adv Exp Med Biol. 189:299-303, 1985
2. FRIEDMAN EA: Diabetic nephropathy is a hyperglycemic glomerulopathy. Arch Intern Med 142:1269-1270, 1981
3. PORTE D JR, SCHWARTZ MW: Diabetics complications: Why is glucose potentially toxic? Science 272:699-670, 1996
4. CRAVEN PA, STUDER RK, NEGRETE H, DERUBERTIS FR: Protein kinase C in diabetic nephropathy. J Diabetes Complications 9:241-245, 1995
5. VLASSARA H: Recent progress on the biologic and clinical significance of advanced glycosilation end products. J Lab Clin Med 124:19, 1994
6. BROWNLEE M: Glycation products and the pathogenesis of diabetic complications. Diabetic Care 15:1835, 1992
7. MAKITA Z, RADOFF S, RAYFIELD EGJ, et al: Advanced glycolation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
8. YANG CW, VLASSARA H, PETEN EP, et al: Advanced glycation end products up-regulate gene expression found in diabetic glomerular diaease. Proc Natl Acad Sci USA 91:9436, 1994
9. SCHMID-SCHONBEIN H, VOLGER E: Red cell aggregation and red cell deformability in diabetes. Diabetes 25 (Suppl 2):897-902, 1976
10. McMILLAN DE, UTTERBACK NG, LA PUMA J: Reduced erythrocyte deformability in diabetes. Diabetes 27:895-901, 1978
11. SKALAK R, HANSS M, CHIEN S: Indices of filterability of red blood cell suspensions. Biorheology 20:311-316, 1983
12. MILLER JA, GRAVALLESE E, BUNN HF: Nonenzymatic glycosylation of erythrocyte membrane proteins: Relevance to diabetes. J Clin Invest 65:896-901, 1980
13. MAKITA Z, VLASSARA H, BUCALA R: HEMOGLOBIN AGE: A circulating marker of advanced glycosylation. Science 258:651-653, 1992
14. MAEDA N, KON K, IMAIZUMI K, et al: Alteration of rheological properties of human erythrocytes by crosslinking of membrane proteins. Biochim Biophys Acta 735:104-112, 1983
15. VLASSARA H, FUH H, MAKITA Z, et al: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 89:12043-1247, 1992
16. EDELSTEIN D, BROWNLEE M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29, 1992
17. BROWN CD, ZHAO ZH, DE ALVARO F, et al: Correlation of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine. Diabetes 16:590-593, 1993
18. BROWN CD, ZHAO ZH,THOMAS LL, et al: Pimagedine improves RBC deformability in diabetic patients with ESRD. FASEB J A6:14, 2000
19. REID HL, BARNES AJ, LOCK PJ, et al: A simple method for measuring erythrocyte deformability. J Clin Pathol 29:855-858, 1976
20. BROWN CD, ZHAO ZH, BERWEEK S, et al: Effects of alloxan-induced diabetes on hemorheology in rabbits. Horm Metabol Res 24:254-257, 1992
21. STUART J, STONE PCW, BAREFORD D, BILTO YY: Effect of pore diameter and cell volume on erythrocyte filterability. Clin Hemorheol 5:449-461, 1985
22. STUART J, STONE PCW, BAREFORD D, et al: Evaluation of leucocyte removal methods for studies of erythrocyte deformability. Clin Hemorheol 5:137-147, 1985
23. GREGERSEN MI, BRYANT CA, HAMMERLE WE, et al: Flow characteristics of human erythrocytes through polycarbonate sieves. Science 157:825-827, 1967
24. RAINHART WH, USAMI S, SCHMALZER EA, et al: Evaluation of red blood cell filterability test: Influences of pore size on hematocrit level, and flow rate. J Lab Clin Med 104:501-516, 1984
25. KENNY MW, MEAKIN M, STUART J: Methods for removal of leucocytes and platelets prior to study of erythrocyte deformability. Clin Hemorheol 3:191-200, 1983
26. NORTON JM, RAND WP: Decreased deformability of erythrocytes from smokers. Blood 57:671-674, 1981
27. LEBLOND PF, COULOMBE L: The measurement of erythrocyte deformability using micropore membranes. A sensitive technique with clinical application. J Lab Clin Med 94:133, 1979
28. BABA Y, KAI M, KAMADA T, et al: Higher levels of erythrocyte microviscosity in diabetes. Diabetes 28:1138-1140, 1979
29. ROBEY C, DASMAHAPATRA A, COHEN MP, SUAREZ S: Sorbinil partially prevents decreased erythrocyte deformability in experimental diabetes mellitus. Diabetes 36:1010-1013, 1987
30. ODANI H, SHINZATO T, USAMI J, et al: Imidazolium cross-links derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients. FEBS Lett 427:381-385, 1998
31. ODETTI P, FORGARTY J, SELL DR, MONNIER VM: Chromatographic quantitation of plasma end erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153-159, 1992
32. γ-(carboxymethyl) lysine is increased in uremia. Kidney Int 52:1064-1067, 1997
33. MIYATA T, WADA Y, CAI Z, et al: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181, 1997
34. MIYATA T, Fu MX, KUROKAWA K, et al: Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Evidence for a generalized increase in oxidative stress in uremia? Kidney Int 54:1290-1295, 1998
35. VLASSORA H: Serum advanced glycosylation end products: A new class of uremic toxin? Blood Purif 12:54-59, 1994